Antiretroviral pharmacokinetic changes in special situations: a narrative review

Authors

DOI:

https://doi.org/10.33448/rsd-v10i12.20198

Keywords:

Antiretrovirals; Pharmacokinetic; HIV.

Abstract

The number of new cases of HIV infection has been steadily increasing. In the world scenario, there is an increase in access to antiretroviral therapy and, currently, 26 million people use antiretrovirals. In Brazil, a country that provides full and free access to antiretrovirals, about 630 thousand people are undergoing treatment. This study aims to describe the pharmacokinetic changes of antiretrovirals in patients with different physiological conditions. A bibliographic survey was carried out with studies related to the use of antiretrovirals in specific groups: extremes of age (newborns and elderly), pregnancy, liver diseases, chronic kidney disease, cardiovascular disease, obesity and metabolic disorders, dietary interactions, use and abuse of legal and illegal drugs and genetic polymorphism. In certain situations, changes in pharmacokinetic parameters such as absorption, distribution, metabolism and excretion were observed, as well as variations in plasma levels of antiretrovirals. In the investigated groups, the importance of dose adjustment is highlighted to increase the effectiveness of antiretrovirals, aiming to provide a more adequate treatment to people living with HIV. 

Author Biography

Cristina Sanches, Universidade Federal de São João del-Rei

Universidade Federal de São João del-Rei (UFSJ), Campus Centro-Oeste Dona Lindu. Rua Sebastião Gonçalves Coelho, 400. Bairro Chanadour. CEP: 35501-296. Divinópolis, Minas Gerais, Brasil. Telefone: (37) 991100301

References

AIDSINFO. (2018). Recommendations for the use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States. Retrieved from https://aidsinfo.nih.gov/guidelines/htmltables/3/6656

AIDSINFO. (2019). Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Retrieved from https://aidsinfo.nih.gov/guidelines/html/2/pediatric-arv/50/maternal-hiv-testing-and-identification-of-perinatal-hiv-exposure

Araújo, P. D., & Ehrhardt, A. (2015). Avaliação do dano hepático em pacientes HIV positivo sob terapia antirretroviral no município de Carazinho/RS. Saúde e Desenvolvimento Humano, 3(2), 45–54. https://doi.org/10.18316/2317-8582.15.4

Bastos, F. I. P. M., Vasconcellos, M. T. L. de, De Boni, R. B., Reis, N. B. dos, & Coutinho, C. F. de S. (2017). III Levantamento Nacional sobre o uso de drogas pela população brasileira. Rio de Janeiro: ICICT/FIOCRUZ. Retrieved from ICICT/FIOCRUZ website: https://www.arca.fiocruz.br/handle/icict/34614

Benaboud, S., Hirt, D., Launay, O., Pannier, E., Firtion, G., Rey, E., … Tréluyera, J. M. (2012). Pregnancy-related effects on tenofovir pharmacokinetics: A population study with 186 women. Antimicrobial Agents and Chemotherapy, 56(2), 857–862. https://doi.org/10.1128/AAC.05244-11

Benaboud, S., Tréluyer, J. M., Urien, S., Blanche, S., Bouazza, N., Chappuy, H., … Hirt, D. (2012). Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women. Antimicrobial Agents and Chemotherapy, 56(2), 776–782. https://doi.org/10.1128/AAC.00370-11

Benedetti, M. S., Whomsley, R., & Canning, M. (2007). Drug metabolism in the paediatric population and in the elderly. Drug Discovery Today, 12(15–16), 599–610. https://doi.org/10.1016/j.drudis.2007.06.011

Best, B. M., Mirochnick, M., Capparelli, E. V., Stek, A., Burchett, S. K., Holland, D. T., … Connor, J. D. (2006). Impact of pregnancy on abacavir pharmacokinetics. Aids, Vol. 20, pp. 553–560. https://doi.org/10.1097/01.aids.0000210609.52836.d1

Bracchi, M., Stuart, D., Castles, R., Khoo, S., Back, D., & Boffito, M. (2015). Increasing use of “party drugs” in people living with HIV on antiretrovirals: A concern for patient safety. AIDS, 29(13), 1585–1592. https://doi.org/10.1097/QAD.0000000000000786

Brasil. Lei n° 9313, de 13 de novembro de 1996. Dispões sobre a distribuição gratuita de medicamentos aos portadores do HIV e doentes de AIDS. , (1996). Brasília - DF: Diario Oficial da União.

Brasil. (2010). Adesão ao Tratamento Antirretroviral no Brasil: Coletânea de Estudos do Projeto Atar. Retrieved June 2, 2021, from Ministério da Saúde, Secretaria de Vigilância em Saúde Departamento de DST, Aids e Hepatites Virais. website: https://www.nescon.medicina.ufmg.br/biblioteca/imagem/3035.pdf

Brasil. (2018). Protocolo Clínico e Diretrizes Terapêuticas para Manejo da Infecção pelo HIV em Adultos. Retrieved May 26, 2021, from Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância, Prevenção e Controle das Infecções Sexualmente Transmissíveis, do HIV/Aids e das Hepatites Virais website: http://www.aids.gov.br/pt-br/pub/2013/protocolo-clinico-e-diretrizes-terapeuticas-para-manejo-da-infeccao-pelo-hiv-em-adultos

BRASIL. (2019). Boletim epidemiológico. Brasília. Retrieved from http://www.aids.gov.br/pt-br/pub/2019/boletim-epidemiologico-de-hivaids-2019

Brito, D. M. S. de. (2012). Guia de cuidados aos pacientes em uso de terapia antirretroviral.

Calcagno, A., Cusato, J., D’Avolio, A., & Bonora, S. (2017). Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs. Clinical Pharmacokinetics, 56(4), 355–369. https://doi.org/10.1007/s40262-016-0456-6

Canals, F., Masiá, M., & Gutiérrez, F. (2018). Developments in early diagnosis and therapy of HIV infection in newborns. Expert Opinion on Pharmacotherapy, 19(1), 13–25. https://doi.org/10.1080/14656566.2017.1363180

Capparelli, E. V., Mirochnick, M., Dankner, W. M., Blanchard, S., Mofenson, L., McSherry, G. D., … Oram, R. (2003). Pharmacokinetics and tolerance of zidovudine in preterm infants. Journal of Pediatrics, 142(1), 47–52. https://doi.org/10.1067/mpd.2003.mpd0335

CDC. (2017, August). HIV infection and older Americans: The public health perspective. American Journal of Public Health, Vol. 102, pp. 1516–1526. https://doi.org/10.2105/AJPH.2012.300844

Chang, P., & Friedenberg, F. (2014). Obesity and GERD. Gastroenterology Clinics of North America, 43(1), 161–173. https://doi.org/10.1016/j.gtc.2013.11.009

Chastain, D. B., Henderson, H., & Stover, K. R. (2015). Epidemiology and Management of Antiretroviral-Associated Cardiovascular Disease. The Open AIDS Journal, 9(1), 23–37. https://doi.org/10.2174/1874613601509010023

Connor, E. M., Sperling, R. S., Gelber, R., Kiselev, P., Scott, G., O’sullivan, M. jo, … Balsley, J. (1994). Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. New England Journal of Medicine, 331(18), 1173–1180. https://doi.org/10.1056/NEJM199411033311801

Costantine, M. M. (2014). Physiologic and pharmacokinetic changes in pregnancy. Frontiers in Pharmacology, 5 APR(April), 1–5. https://doi.org/10.3389/fphar.2014.00065

Courlet, P., Stader, F., Guidi, M., Saldanha, S. A., Stoeckle, M., Cavassini, M., … Marzolini, C. (2019). Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging patients enrolled in the Swiss HIV Cohort Study. Aids, 1. https://doi.org/10.1097/qad.0000000000002372

Cressey, T. R., & Lallemant, M. (2007). Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: An update. Infection, Genetics and Evolution, Vol. 7, pp. 333–342. Elsevier. https://doi.org/10.1016/j.meegid.2006.08.004

Dawes Bsc, M., & Chowienczyk Bsc, P. J. (2001). Pharmacokinetics in pregnancy Lecturer in Clinical Pharmacology. 15(6), 819–826. https://doi.org/10.1053/beog.2001.0231

De Sousa Mendes, M., & Chetty, M. (2019). Are Standard Doses of Renally-Excreted Antiretrovirals in Older Patients Appropriate: A PBPK Study Comparing Exposures in the Elderly Population With Those in Renal Impairment. Drugs in R and D, (0123456789). https://doi.org/10.1007/s40268-019-00285-0

Dupin, N., Buffet, M., Marcelin, A. G., Lamotte, C., Gorin, I., Ait-Arkoub, Z., … Peytavin, G. (2002). HIV and antiretroviral drug distribution in plasma and fat tissue of HIV-infected patients with lipodystrophy. AIDS, 16(18), 2419–2424. https://doi.org/10.1097/00002030-200212060-00006

Eichelbaum, M., Ingelman-Sundberg, M., & Evans, W. E. (2006). Pharmacogenomics and individualized drug therapy. Annual Review of Medicine, 57, 119–137. https://doi.org/10.1146/annurev.med.56.082103.104724

Ekrikpo, U. E., Kengne, A. P., Bello, A. K., Effa, E. E., Noubiap, J. J., Salako, B. L., … Okpechi, I. G. (2018). Chronic kidney disease in the global adult HIV-infected population: A systematic review and meta-analysis. PLoS ONE, 13(4), 1–24. https://doi.org/10.1371/journal.pone.0195443

Ellis, C. L. (2017). HIV associated kidney diseases: Clarifying concordance between renal failure in HIV infection and histopathologic manifestations at kidney biopsy. Seminars in Diagnostic Pathology, 34(4), 377–383. https://doi.org/10.1053/j.semdp.2017.04.009

Estrela, C. (2018). Metodologia Científica: Ciência, Ensino, Pesquisa. Editora Artes Médicas.

Evans, W. E., & Relling, M. V. (1999, October 15). Pharmacogenomics: Translating functional genomics into rational therapeutics. Science, 286(5439), 487–491. https://doi.org/10.1126/science.286.5439.487

Ferreira, V. M. B. (2004). ÁLCOOL, DROGAS ILÍCITAS E ANTI-RETROVIRAIS. Retrieved from https://www.saude.sc.gov.br/index.php/informacoes-gerais-documentos/conferencias-e-encontros/conferencia-estadual-de-saude-mental/textos/3163-alcool-droga-ilicita/file

Friedl, D. B., Aprile, D. C. B., Fino, L. C., Barbosa, D. A., & Belasco, A. G. S. (2009). Evolução da função renal de pacientes portadores do Vírus da Imunodeficiência Humana/ Síndrome da Imunodeficiência Adquirida. Acta Paulista de Enfermagem, 22(spe1), 531–534. https://doi.org/10.1590/s0103-21002009000800016

Ganesan, M., Poluektova, L. Y., Kharbanda, K. K., & Osna, N. A. (2018). Liver as a target of human immunodeficiency virus infection. World Journal of Gastroenterology, 24(42), 4728–4737. https://doi.org/10.3748/wjg.v24.i42.4728

Gauthier, I., & Malone, M. (1998). Drug-food interactions in hospitalised patients. Drug Safety, 18(6), 383–393. https://doi.org/10.2165/00002018-199818060-00001

Gilbert, E. M., Darin, K. M., Scarsi, K. K., & McLaughlin, M. M. (2015). Antiretroviral pharmacokinetics in pregnant women. Pharmacotherapy, 35(9), 838–855. https://doi.org/10.1002/phar.1626

Guaraldi, G., Pintassilgo, I., Milic, J., & Mussini, C. (2018). Managing antiretroviral therapy in the elderly HIV patient. Expert Review of Clinical Pharmacology, 11(12), 1171–1181. https://doi.org/10.1080/17512433.2018.1549484

Hall, A. M., Hendry, B. M., Nitsch, D., & Connolly, J. O. (2011). Tenofovir-associated kidney toxicity in HIV-infected patients: A review of the evidence. American Journal of Kidney Diseases, 57(5), 773–780. https://doi.org/10.1053/j.ajkd.2011.01.022

Hürlimann, D., Chenevard, R., Ruschitzka, F., Flepp, M., Enseleit, F., Béchir, M., … Weber, R. (2006). Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing anti-retroviral combination therapy: A randomised double blind crossover trial. Heart, 92(1), 110–112. https://doi.org/10.1136/hrt.2004.056523

Ishizaki, A., Cuong, N. H., Thuc, P. Van, Trung, N. V., Saijoh, K., Kageyama, S., … Ichimura, H. (2009). Profile of HIV type 1 infection and genotypic resistance mutations to antiretroviral drugs in treatment-naive HIV type 1-infected individuals in Hai Phong, Viet Nam. AIDS Research and Human Retroviruses, 25(2), 175–182. https://doi.org/10.1089/aid.2008.0193

Jain, R., Chung, S. M., Jain, L., Khurana, M., Lau, S. W. J., Lee, J. E., … Sahajwalla, C. G. (2011). Implications of obesity for drug therapy: Limitations and challenges. Clinical Pharmacology and Therapeutics, 90(1), 77–89. https://doi.org/10.1038/clpt.2011.104

Jourjy, J., Dahl, K., & Huesgen, E. (2015). Antiretroviral treatment efficacy and safety in older HIV-infected adults. Pharmacotherapy, 35(12), 1140–1151. https://doi.org/10.1002/phar.1670

Kaspar, M. B., & Sterling, R. K. (2017). Mechanisms of liver disease in patients infected with HIV. BMJ Open Gastroenterology, 4(1), 1–7. https://doi.org/10.1136/bmjgast-2017-000166

Khalsa, J. H., Talal, A. H., & Morse, G. (2017). Drug–Drug Interactions and Diagnostics for Drug Users With HIV and HIV/HCV Coinfections: Introduction. Clinical Pharmacology in Drug Development, 6(2), 108–117. https://doi.org/10.1002/cpdd.316

Kim, M. H., Ahmed, S., & Abrams, E. J. (2016). Paediatric HIV : Progress on Prevention , Treatment and Cure. 3(3), 219–229. https://doi.org/10.1007/s40124-015-0087-7.Paediatric

King, J. R., Kimberlin, D. W., Aldrovandi, G. M., & Acosta, E. P. (2002). Antiretroviral Pharmacokinetics in the Paediatric Population A Review. Infancy, 41(14), 1115–1133.

Klotz, U., Schwab, M., & Treiber, G. (2004). CYP2C19 polymorphism and proton pump inhibitors. Basic and Clinical Pharmacology and Toxicology, 95(1), 2–8. https://doi.org/10.1111/j.1600-0773.2004.pto950102.x

Ku, C. L., & Smith, B. P. (2011). Dosing in neonates: Special considerations in physiology and trial design. Bone, 23(1), 1–7. https://doi.org/10.1038/jid.2014.371

Kumar, S., Rao, P. S. S., Earla, R., & Kumar, A. (2015). Drug-drug interactions between anti-retroviral therapies and drugs of abuse in HIV systems. Expert Opinion on Drug Metabolism and Toxicology, 11(3), 343–355. https://doi.org/10.1517/17425255.2015.996546

Lombardo, M., & Eserian, J. K. (2014). FÁRMACOS E ALIMENTOS: INTERAÇÕES E INFLUÊNCIAS NA TERAPÊUTICA. Infarma - Ciências Farmacêuticas, 26(3), 188–192. https://doi.org/10.14450/2318-9312.v26.e3.a2014.pp188-192

López, J. C., Moreno, S., Jiménez-Oñate, F., Clotet, B., Rubio, R., & Hernández-Quero, J. (2006). A cohort study of the food effect on virological failure and treatment discontinuation in patients on HAART containing didanosine enteric-coated capsules (FOODDle study). HIV Clinical Trials, 7(4), 155–162. https://doi.org/10.1310/hct0704-155

Madelain, V., Le, M. P., Champenois, K., Charpentier, C., Landman, R., Joly, V., … Peytavin, G. (2017). Impact of obesity on antiretroviral pharmacokinetics and immunovirological response in HIV-infected patients: A case-control study. Journal of Antimicrobial Chemotherapy, 72(4), 1137–1146. https://doi.org/10.1093/jac/dkw527

Mangoni, A. A., & Jackson, S. H. D. (2004). Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications. British Journal of Clinical Pharmacology, 57(1), 6–14. https://doi.org/10.1046/j.1365-2125.2003.02007.x

Mcdowell, J. A., Chittick, G. E., Stevens, C. P., Edwards, K. D., & Stein, D. S. (2000). Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. Antimicrobial Agents and Chemotherapy, 44(6), 1686–1690. https://doi.org/10.1128/AAC.44.6.1686-1690.2000

Medeiros, J. L., & Ferreira, M. L. H. (1998). Cirrose Hepática e Insuficiência hepática. Terapêutica Clínica. Rio de Janeiro: Guanabara Koogan.

Menezes, A. M., Torelly, J., Real, L., Bay, M., Poeta, J., & Sprinz, E. (2011). Prevalence and risk factors associated to chronic kidney disease in HIV-infected patients on HAART and undetectable viral load in Brazil. PLoS ONE, 6(10). https://doi.org/10.1371/journal.pone.0026042

Metzger, I. F., Souza-Costa, D. C., & Tanus-Santos, J. E. (2006). Farmacogenética: Princípios, aplicações e perspectivas. Medicina, 39(4), 515–521. https://doi.org/10.11606/issn.2176-7262.v39i4p515-521

Mocroft, A., Kirk, O., Reiss, P., De Wit, S., Sedlacek, D., Beniowski, M., … EuroSIDA Study Group. (2010). Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS, 24(11), 1667–1678. https://doi.org/10.1097/QAD.0b013e328339fe53

Nadaleto, B. F., Herbella, F. A. M., & Patti, M. G. (2016). Gastroesophageal reflux disease in the obese: Pathophysiology and treatment. Surgery (United States), 159(2), 475–486. https://doi.org/10.1016/j.surg.2015.04.034

Naicker, S., Rahmanian, S., & Kopp, J. B. (2015). HIV and chronic kidney disease. Clinical Nephrology, 83, S32–S38. https://doi.org/10.5414/CNP83S032

NCBI. (2019). National Center for Biotechnology Information. Retrieved August 20, 2021, from https://www.ncbi.nlm.nih.gov/

Neto, L. F. da S. P., Bassetti, B. R., Fraga, I. H. V., Oliveira Santos, C. R., Ximenes, P. D., & Miranda, A. E. (2016). Nephrotoxicity during tenofovir treatment: A three-year follow-up study in a Brazilian reference clinic. Brazilian Journal of Infectious Diseases, 20(1), 14–18. https://doi.org/10.1016/j.bjid.2015.09.004

Nettles, R. E., Kieffer, T. L., Parsons, T., Johnson, J., Cofrancesco, J., Gallant, J. E., … Flexner, C. (2006). Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clinical Infectious Diseases, 42(8), 1189–1196. https://doi.org/10.1086/501458

Nuh, O. (2020). Interactions between HIV treatment and recreational drugs. Retrieved May 26, 2021, from Chemsex & recreational drug use website: https://www.aidsmap.com/about-hiv/interactions-between-hiv-treatment-and-recreational-drugs

Nunes, E. P. (2016). Terapia antirretroviral e função renal. The Brazilian Journal of Infectious Diseases, 2(3), 82–90. Retrieved from https://www.bjid.org.br/en-terapia-antirretroviral-e-funcao-renal-articulo-X217751171655969X

Núñez, M. (2010). Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology, 52(3), 1143–1155. https://doi.org/10.1002/hep.23716

Oliveira, N. M., Ferreira, F. A. Y., Yonamine, R. Y., & Chehter, E. Z. (2014). Drogas antirretrovirais e pancreatite aguda em pacientes com HIV/AIDS: existe alguma associação? Revisão da literatura. Einstein, 12(1). Retrieved from https://www.scielo.br/j/eins/a/kdTPqNZS7Ymkn7MfW5kX6Sv/?lang=pt&format=pdf

Pacifici, G. M. (2005). Pharmacokinetics of antivirals in neonate. Early Human Development, 81(9), 773–780. https://doi.org/10.1016/j.earlhumdev.2005.06.001

Pariente, G., Leibson, T., Carls, A., Adams-Webber, T., Ito, S., & Koren, G. (2016). Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review. PLoS Medicine, 13(11), 1–36. https://doi.org/10.1371/journal.pmed.1002160

Pezzani, M. D., Resnati, C., Di Cristo, V., Riva, A., & Gervasoni, C. (2016). Abacavir-induced liver toxicity. Brazilian Journal of Infectious Diseases, 20(5), 502–504. https://doi.org/10.1016/j.bjid.2016.03.002

Post, F. A., & Holt, S. G. (2009). Recent developments in HIV and the kidney. Current Opinion in Infectious Diseases, 22(1), 43–48. https://doi.org/10.1097/QCO.0b013e328320ffec

Queiroz, M. A. F., Laurentino, R. V., Amoras, E. da S. G., Araújo, M. S. M. de, Gomes, S. T. M., Lima, S. S., … Machado, L. F. A. (2017). The CYP2B6 G516T polymorphism influences CD4+ T-cell counts in HIV-positive patients receiving antiretroviral therapy in an ethnically diverse region of the Amazon. International Journal of Infectious Diseases, 55, 4–10. https://doi.org/10.1016/j.ijid.2016.12.002

Rakhmanina, N., & Phelps, B. R. (2012). Pharmacotherapy of Pediatric HIV Infection. Pediatric Clinics of North America, 59(5), 1093–1115. https://doi.org/10.1016/j.pcl.2012.07.009

Raposeiras-Roubín, S., & Triant, V. (2016). Ischemic Heart Disease in HIV: An In-depth Look at Cardiovascular Risk. Revista Española de Cardiología (English Edition), 69(12), 1204–1213. https://doi.org/10.1016/j.rec.2016.10.005

Reynes, J., Pevriere, H., De Boever, C., & Le Moing, V. (2003). Renal tubular injury and severe hypophosphoremia (Fanconi syndrome) associated with tenofovir therapy [poster 717]. In Program an Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. Boston, USA. Alexandria, VA: Foundation for Retrovirology and Human Health.

Ritschel, W. A., & Kearns, G. L. (2009). Handbook of Basic Pharmacokinetics Including Clinical Applications (7 th ed.). The American Pharmacists Association. https://doi.org/10.21019/9781582121260

Rodighiero, V. (1989). EFFECTS OF CARDIOVASCULAR DISEASE ON PHARMACOKINETICS SUMMARY. Cardiovascular Drugs and Therapy, 3, 711–730.

Rongkavilit, C., Thaithumyanon, P., Chuenyam, T., Damle, B. D., Limpongsanurak, S., Boonrod, C., … Phanuphak, P. (2001). Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates. Antimicrobial Agents and Chemotherapy, 45(12), 3585–3590. https://doi.org/10.1128/AAC.45.12.3585-3590.2001

Santos, W. M. Dos, Secoli, S. R., & Padoin, S. M. de M. (2016). Potential drug interactions in patients given antiretroviral therapy. Revista Latino-Americana de Enfermagem, 24. https://doi.org/10.1590/1518-8345.1193.2832

Schijvens, A. M., Wildt, S. N. de, & Schreuder, M. F. (2020). Pharmacokinetics in children with chronic kidney disease. Pediatric Nephrology, 35(7), 1153–1172. https://doi.org/10.1007/s00467-019-04304-9

Schoen, J. C., Erlandson, K. M., & Anderson, P. L. (2013). Clinical pharmacokinetics of antiretroviral drugs in older persons. Expert Opinion on Drug Metabolism and Toxicology, 9(5), 573–588. https://doi.org/10.1517/17425255.2013.781153

Simões, G. L. D. B. A., Camera, P., Pacheco, A., & Nascimento, R. E. do. (2020). Polimorfismos genéticos no receptor da vitamina D e a suscetibilidade a doenças no Brasil. Revista de Patologia Do Tocantins, 7(2), 83–87. https://doi.org/10.20873/uft.2446-6492.2020v7n2p83

Singh, H. O., Samani, D., Nain, S., & Dhole, T. N. (2019). Interleukin-10 polymorphisms and susceptibility to ARV associated hepatotoxicity. Microbial Pathogenesis, 133. https://doi.org/10.1016/j.micpath.2019.103544

Smit, C., Hoogd, S. de, Brüggemann, R. J. M., & Knibbe, C. A. J. (2018). Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. Expert Opinion on Drug Metabolism and Toxicology, 14(3), 275–285. https://doi.org/10.1080/17425255.2018.1440287

Soeria-Atmadja, S., Österberg, E., Gustafsson, L. L., Dahl, M. L., Eriksen, J., Rubin, J., & Navér, L. (2017). Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin. PLoS ONE, 12(9). https://doi.org/10.1371/journal.pone.0181316

Souza, D. S. de, Hora, T. F. da, Padilha, P. de C., Gonçalves, J. C. S., & Peres, W. A. F. (2014). Efeito dos alimentos na biodisponibilidade de medicamentos antirretrovirais: uma revisão sistemática da literatura. Nutrire, 39(2), 243–251. https://doi.org/10.4322/nutrire.2014.023

Souza, J. de, & Storpirtis, S. (2004). Antiretroviral activity and pharmacokinetics properties of lamivudine and zidovudine association. Revista Brasileira de Ciencias Farmaceuticas/Brazilian Journal of Pharmaceutical Sciences, 40(1), 9–19. https://doi.org/10.1590/s1516-93322004000100004

Spina, E., Santoro, V., & D’Arrigo, C. (2008). Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update. Clinical Therapeutics, 30(7), 1206–1227. https://doi.org/10.1016/S0149-2918(08)80047-1

Stader, F., Kinvig, H., Penny, M. A., Battegay, M., Siccardi, M., & Marzolini, C. (2019). Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly. Clinical Pharmacokinetics, (0123456789). https://doi.org/10.1007/s40262-019-00822-9

Stolbach, A., Paziana, K., Heverling, H., & Pham, P. (2015). A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine Products. Journal of Medical Toxicology, 11(3), 326–341. https://doi.org/10.1007/s13181-015-0465-0

Sudano, I., Spieker, L. E., Noll, G., Corti, R., Weber, R., & Lüscher, T. F. (2006). Cardiovascular disease in HIV infection. American Heart Journal, 151(6), 1147–1155. https://doi.org/10.1016/j.ahj.2005.07.030

Sulkowski, M. S., Thomas, D. L., Mehta, S. H., Chaisson, R. E., & Moore, R. D. (2002). Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology, 35(1), 182–189. https://doi.org/10.1053/jhep.2002.30319

Svärd, J., Spiers, J. P., Mulcahy, F., & Hennessy, M. (2010). Nuclear receptor-mediated induction of CYP450 by antiretrovirals: Functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans. Journal of Acquired Immune Deficiency Syndromes, 55(5), 536–549. https://doi.org/10.1097/QAI.0b013e3181f52f0c

Swanepoel, C. R., Atta, M. G., D’Agati, V. D., Estrella, M. M., Fogo, A. B., Naicker, S., … Zeier, M. (2018). Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 93(3), 545–559. https://doi.org/10.1016/j.kint.2017.11.007

Terada, T., & Hira, D. (2015). Intestinal and hepatic drug transporters: pharmacokinetic, pathophysiological, and pharmacogenetic roles. Journal of Gastroenterology, 50(5), 508–519. https://doi.org/10.1007/s00535-015-1061-4

Thapa, R. K., Choi, H. G., Kim, J. O., & Yong, C. S. (2017). Analysis and optimization of drug solubility to improve pharmacokinetics. Journal of Pharmaceutical Investigation, 47(2), 95–110. https://doi.org/10.1007/s40005-016-0299-z

Triant, V. A. (2013). Cardiovascular Disease and HIV Infection Virginia. Curr HIV/AIDS, 10(3), 199–206. https://doi.org/10.1007/s11904-013-0168-6.Cardiovascular

UNAIDS. (2019a). Joint United Nations Programme on HIV/AIDS. Retrieved May 28, 2021, from Country fact sheet: Brazil 2019 website: https://www.unaids.org/en/regionscountries/countries/brazil

UNAIDS. (2019b). Joint United Nations Programme on HIV/AIDS. Retrieved May 24, 2021, from https://www.unaids.org/en/resources/documents/2019/2019-UNAIDS-d

UNAIDS. (2020). Joint United Nations Programme on HIV/AIDS. Retrieved May 24, 2021, from Fact sheet – World Aids Day 2020. Global HIV Statistics website: https://www.unaids.org/en/resources/documents/2020

Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., … Zhu, X. (2001). The sequence of the human genome. Science, 291(5507), 1304–1351. https://doi.org/10.1126/science.1058040

Verma, S., & Kaplowitz, N. (2009). Diagnosis, management and prevention of drug-induced liver injury. General Medicine, 58(11), 1555–1564. https://doi.org/10.1136/gut.2008.163675

Violari, A., PH, D., Steyn, J., Sc, M., Madhi, S. A., Paed, F. C., … Jean-philippe, P. (2008). Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV- infected infants. N Engl J Med. Nov 2008;359(21):2233-2244. 359(21), 2233–2244. https://doi.org/10.1056/NEJMoa0800971.Early

Winston, A., Bloch, M., Carr, A., Amin, J., Mallon, P. W. G., Ray, J., … Emery, S. (2005). Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 56(2), 380–387. https://doi.org/10.1093/jac/dki235

Winter, M. E. (2004). Basic clinical pharmacokinetics (4th ed). United States: Philadelphia : Lippincott Williams & Wilkins, c2004.

Won, C. S., Oberlies, N. H., & Paine, M. F. (2012). Mechanisms underlying food-drug interactions: Inhibition of intestinal metabolism and transport. Pharmacology and Therapeutics, 136(2), 186–201. https://doi.org/10.1016/j.pharmthera.2012.08.001

Yellepeddi, V. (2016). Princípios da terapia medicamentosa (6 ed.; Artmed, Ed.). Porto Alegre: Whalen, K. et al. Farmacologia Ilustrada.

Published

14/09/2021

How to Cite

BERNARDES, G. C. S.; SALES, T. L. S.; SANTOS, M. T. A.; ROCHA, B. G.; COSTA, A. C. de M.; CASTRO, A. P. de; RESENDE, C. A. A.; SANCHES, C. Antiretroviral pharmacokinetic changes in special situations: a narrative review. Research, Society and Development, [S. l.], v. 10, n. 12, p. e108101220198, 2021. DOI: 10.33448/rsd-v10i12.20198. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/20198. Acesso em: 29 feb. 2024.

Issue

Section

Health Sciences